ClinicalTrials.gg
CompletedNCT03638869Updated Aug 20, 2018

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)

A Phase 1 interventional study of REL-1017 and Placebo in Neuropathic Pain, sponsored by Relmada Therapeutics, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-20.

Sponsored by Relmada Therapeutics, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Aug 2015, registered Aug 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study evaluated the safety, tolerance, and pharmacokinetics (PK) of d-methadone in a limited dose range, in multiple administrations in humans.

Read the detailed description

This was a phase 1, single-center study carried out in healthy male and female subjects to investigate the safety, tolerability, and PK of multiple doses (25mg, 50mg, and 75mg once daily) of d-methadone for 10 days. It was a double-blind, randomized, placebo-controlled study in sequential cohorts of healthy subjects. Subjects participated in the study for approximately 7 weeks. Eligible subjects were randomized within 30 days of screening. Of the 8 subjects in each cohort, 2 subjects received placebo and 6 subjects received d-methadone. The duration of dosing ensured that steady-state plasma concentrations were achieved.

A single ascending dose study previously conducted by Relmada Therapeutics, Inc. demonstrated that the maximum tolerated single dose for oral d-methadone in healthy opiate-naive subjects was 150 mg. The single doses of d-methadone appeared to be safe, with no indication of respiratory depression or clinically significant QTc prolongation, and minimal subjective pharmacodynamic (PD) effects.

The following assessments and procedures ensured the safety of the subjects during the study:

  • continuous cardiac telemetry for 8 hours post-dose to detect any potential cardiac issues
  • continuous pulse oximetry monitoring for 8 hours post-dose to detect any potential respiratory distress
  • presence of a safety catheter to administer rescue medication (naloxone), if needed

The following signs of opioid toxicity were deemed to be of special interest:

  • sustained respiratory depression that results in oxygen saturation below 92%
  • QTc prolongation (>500 ms or >70 ms above the baseline)
  • protracted nausea and vomiting
  • any AE deemed by the investigator to be dose-limiting Safety Analysis Safety and tolerability parameters were listed by treatment and subject and displayed in summary tables using descriptive statistics. Original terms used to identify AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 17.1. The number and percentage of subjects with treatment emergent AEs (TEAEs) were summarized by system organ class, preferred term, and treatment and for each treatment by maximum intensity and maximum relationship to study treatment.

Descriptive statistics for vital signs were calculated and presented for each time point by treatment group (absolute values and change from baseline). Safety ECG results were summarized using descriptive statistics; frequencies (numbers and percentages) were calculated for the overall evaluation by scheduled time and treatment group. Laboratory data were summarized by the type of test and scheduled visit. Descriptive statistics and number of subjects with laboratory test results below, within, and above normal ranges were tabulated by scheduled time. Abnormal findings in laboratory data were listed with a flag for clinical significance. Medical history abnormalities were coded to MedDRA terms and listed. Physical examination abnormalities were also listed. Data collected from the C-SSRS were classified into the Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories and were listed. Frequency tables were used to summarize the total score from the COWS questionnaire, by treatment group. The original verbatim terms for concomitant medications were coded into drug class and preferred term. These data were listed.

Pharmacokinetic Analysis The PK parameters for d-methadone determined by non-compartmental analysis were summarized by dose. Graphs of concentration (linear and log-linear) vs time were generated. Descriptive statistics were calculated by dose and time point for all d-methadone concentrations. Concentrations below the limit of quantification (BLQ) were analyzed as outlined in the statistical analysis plan (SAP). Concentrations of l-methadone were analyzed only if the majority of values were not BLQ.

For the calculation of the PK parameters, concentration-time data were treated as follows: BLQ concentrations prior to the first quantifiable concentration were set to zero; BLQ concentrations after the first quantifiable concentration were treated as missing; pre-dose sampling times relative to dosing were set to zero. Descriptive statistics were calculated by dose. The dose proportionality of Cmax and AUC was assessed by the Hummel method. Tmax and t½ for different doses were compared using the Kruskal-Wallis test.

Pharmacodynamic Analysis The PD data at each time point were summarized by descriptive statistics and presented graphically (as appropriate). Derived endpoints were summarized using descriptive statistics. Pupillometry constriction was listed and grouped by treatment group and subject with descriptive statistics for changes from baseline for different time points.

Holter ECG Analysis (Cardiodynamic Analysis) The analysis of the Holter ECG data was performed using SAS®. The average of the 3 pre-dose time points on Day 1 was used as baseline for all post-dose time points. Heart rate and the PR, QRS, QT, and QTcF intervals collected from all randomized subjects were presented in data listings with the same precision as in the database. Data listings were sorted by treatment, subject number, day, and time point. Both absolute and change from baseline values for each subject were provided.

02

Conditions studied

  • Neuropathic Pain

Browse trials for

03

In context

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

This study's enrollment of 24 is below the median of 52 across 831 interventional studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

Relmada Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. healthy male or female subjects, 18 to 55 years of age, inclusive
  2. (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive, and a minimum weight of 50.0 kg
  3. non-smoker for at least 3 months and tested negative on a breath carbon monoxide (CO) test
  4. male subjects of must have been using and willing to continue using medically acceptable from screening and for at least 2 months after the last study drug administration
  5. female subjects of must have been using and willing to continue using medically acceptable contraception for at least 1 month prior to screening (at least 3 months for oral, transdermal, vaginal ring contraceptives) and for at least 2 months after last study drug administration
  6. female subjects of non-childbearing potential must have met the criteria defined in the clinical protocol
  7. able to speak, read, and understand English sufficiently to allow completion of all study assessments
  8. must have understood and provided written , prior to the initiation of any protocol-specific procedures

Exclusion criteria

Exclusion Criteria:

  1. self-reported substance or alcohol dependence (excluding nicotine and caffeine) within the past 2 years, and/or subjects who had ever been in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence
  2. subject-reported family history of substance abuse in an immediate family member (i.e., parent, sibling, or child)
  3. history or presence of abnormality as assessed by physical examination, medical history, 12-lead , vital signs, or laboratory values, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results
  4. chronic use of prescribed opioids (i.e., >120 days in a 6-month period) or any recreational use of opioids
  5. evidence of clinically significant hepatic or renal impairment, including (ALT) or aspartate aminotransferase (AST) >1.5× (ULN) or >1× ULN
  6. history or family history of sudden unexplained death or long syndrome
  7. QT interval corrected using Fridericia's formula (QTcF) >450 ms in females or >430 ms in males
  8. history of hypotension
  9. history or presence of any condition in which an opioid was (e.g., significant respiratory depression, acute or severe bronchial asthma or hypercarbia, bronchitis, or had/was suspected of having paralytic ileus)
  10. history of status asthmaticus, chronic pulmonary disease, or severe allergic reaction (including anaphylaxis) to any substance
  11. use of an opioid within the 6 months prior to screening
  12. use of a prohibited medication
  13. positive urine drug screen
  14. positive breath alcohol test; subjects with a positive result may have been rescheduled at the investigator's discretion
  15. female subjects who were currently pregnant (had a positive pregnancy test)
  16. history of allergy or to methadone or related drugs (e.g., opioids)
  17. positive for , , or (HIV)
  18. donation or loss of more than 500 mL of whole blood within 30 days prior to first drug administration
  19. difficulty with venous access or unsuitable or unwilling to undergo catheter insertion
  20. treatment with an drug within 5 times the elimination half-life, if known (e.g., a marketed product) or within 30 days (if the elimination half-life is unknown) prior to first drug administration or was concurrently enrolled in any research judged not to be scientifically or medically compatible with this study
  21. an employee of the sponsor or research site personnel directly affiliated with this study or their immediate family member, defined as a spouse, parent, sibling, or child, whether biological or legally adopted
  22. a subject who, in the opinion of the investigator or designee, was considered unsuitable or unlikely to comply with the study protocol for any reason
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Placebo comparator
    Arm 1

    100 mL Ocean Spray® Diet Cranberry Juice

    Drug: Placebo

  • Experimental
    Arm 2

    REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice

    Drug: REL-1017

  • Experimental
    Arm 3

    REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice

    Drug: REL-1017

  • Experimental
    Arm 4

    REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice

    Drug: REL-1017

Interventions

  • The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.

    Also known as: (d-Methadone)

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    Spontaneously reported and observed AEs were recorded throughout the study, and AEs were elicited using a non-leading question at designated time points. Regardless of seriousness, intensity, or presumed relationship to study drug, all AEs were recorded in the source documentation from the time of first contact with the subject (e.g., screening) until the end of the follow-up period of the study. AEs that occurred after medical screening and prior to administration of the first dose of study drug were recorded in the source documentation as baseline signs and symptoms.

    Time frame: Change from pre-dose, Days 1 through 13, and Days 14, 16±1, and 18±1

Secondary outcomes

  1. Plasma levels

    Blood samples were collected to determine the plasma levels of d-methadone and l-methadone.

    Time frame: Days 1 through 13, and Days 14, 16±1, and 18±1

Other outcomes

  1. Clinical Opiate Withdrawal Scale (COWS)

    The Clinical Opiate Withdrawal Scale (COWS) is an 11-item scale designed to be administered by a clinician. This tool can be used in both inpatient and outpatient settings to reproducibly rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. The summed score for the complete scale can be used to help clinicians determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. The sum total of the 11 items are ranked by score. Score: 5- 1 2 = mild; 1 3-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal

    Time frame: Days 11 through 13

  2. Bond-Lader visual analog scale (VAS) assessment

    The Bond-Lader visual analog scale (VAS) consists of 16 bipolar, self-rated, 101-point (from 0 to 100) scales between opposite adjectives. This VAS was adapted for computerized assessment. The subject had to indicate how they were feeling at the time of evaluation. Using a mouse, the subject positioned a cursor over a small vertical box (a "slider") and clicked on it to move it left or right on a horizontal line. To register the response, the subject had to press the "OK" button that appeared below the horizontal line.

    Time frame: Pre-dose and 3 hours post-dose on Day 1 to Day 10 and 72 hours post last dose

  3. Pupillometry

    Pupillometry was used as an objective physiological PD measure as it is a sensitive measure of central opioid action and appears to be resistant to tolerance development with repeated administration. An electronic pupillometer was used to measure pupil diameter. Data from a series of frames were used in the calculation, and the final display showed the weighted average and standard deviation of the pupil size. Measurements were collected under mesopic lighting conditions.

    Time frame: Pre-dose and 2, 4, 6, and 8 hours post-dose from Day 2 to Day 9, and from Day 10 to Day 13

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Nov 2015, 2 months.

Of 36 phase 1 interventional studies under Neuralgia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2018
First posted
Aug 20, 2018
StartActual
Aug 31, 2015
Primary completionActual
Nov 16, 2015
CompletionActual
Nov 16, 2015
Last update
Aug 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03638869
Lead sponsor
Relmada Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Aug 31, 2015
Primary completion
Nov 16, 2015
Completion
Nov 16, 2015
Last update
Aug 20, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-methadone

Start the discussion